Results of treatment for soft tissue sarcoma in childhood and adolescence:: A final report of the German cooperative soft tissue sarcoma study CWS-86

被引:199
作者
Koscielniak, E
Harms, D
Henze, G
Jürgens, H
Gadner, H
Herbst, M
Klingebiel, T
Schmidt, BF
Morgan, M
Knietig, R
Treuner, J
机构
[1] Olga Hosp, Dept Hematol Oncol, D-70176 Stuttgart 1, Germany
[2] Univ Kiel, Inst Paidopathol, Kiel, Germany
[3] Charite Virchow Klinikum, Berlin, Germany
[4] Univ Dusseldorf, Childrens Hosp, D-4000 Dusseldorf, Germany
[5] Univ Regensburg, Dept Radiol, D-8400 Regensburg, Germany
[6] Univ Tubingen, Dept Hematol Oncol, Tubingen, Germany
[7] Katharinen Hosp, Dept Radiotherapy, Stuttgart, Germany
[8] St Anna Kinderspital, Vienna, Austria
关键词
D O I
10.1200/JCO.1999.17.12.3706
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The goal of the second German Soft Tissue Sarcoma Study CWS-86 (1985 to 1990) was to improve the prognosis in children and adolescents with soft tissue sarcoma by means of a clinical trial comprising intensive chemotherapy and risk-adapted local therapy, Patients and Methods: There were 372 eligible patients, A staging system based on the postsurgical extent of disease was used. Chemotherapy consisted of vincristine, dactinomycin, doxorubicin, and ifosfamide. Radiotherapy was administered early at 10 to 13 weeks simultaneously with the second chemotherapy cycle (32 Oy or 54.4 Gy). The single dose was reduced to 1.6 Oy and given twice daily (accelerated hyperfractionation), Results: The event-free survival (EFS) and overall survival rates at 5 years were 59% +/- 3% and 69% +/- 3%, respectively The 5-year EFS rate according to stage was as follows: stage 1, 83% +/- 5%; stage 11, 69% +/- 6%; stage ill, 57% +/- 4%;and stage IV, 19% +/- 6%. The outcome for patients with stage III disease who required radiotherapy was much better in the CWS-86 study compared with the CWS-81 study (5-year EFS, 60% +/- 5% v 44% +/- 6%; P =.053). The most common treatment failure was isolated local relapse, with 14% of patients relapsing at the primary tumor site, Conclusion: The improved design of the study incorporating risk-adapted radiotherapy allowed treatment to be reduced for selected groups of patients without compromising survival. J Clin Oncol 17:3706-3719. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:3706 / 3719
页数:14
相关论文
共 26 条
[1]
BROCK N, 1989, CANCER RES, V49, P1
[2]
THE OXAZAPHOSPHORINES [J].
BROCK, N .
CANCER TREATMENT REVIEWS, 1983, 10 :3-15
[3]
CARLI M, 1991, P ASCO, V11, P319
[4]
CASPER ES, 1991, CANCER, V68, P1221, DOI 10.1002/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO
[5]
2-R
[6]
THE THIRD INTERGROUP RHABDOMYOSARCOMA STUDY [J].
CRIST, W ;
GEHAN, EA ;
RAGAB, AH ;
DICKMAN, PS ;
DONALDSON, SS ;
FRYER, C ;
HAMMOND, D ;
HAYS, DM ;
HERRMANN, J ;
HEYN, R ;
JONES, PM ;
LAWRENCE, W ;
NEWTON, W ;
ORTEGA, J ;
RANEY, RB ;
RUYMANN, FB ;
TEFFT, M ;
WEBBER, B ;
WIENER, E ;
WHARAM, M ;
VIETTI, TJ ;
MAURER, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :610-630
[7]
PROGNOSIS IN CHILDREN WITH RHABDOMYOSARCOMA - A REPORT OF THE INTERGROUP RHABDOMYOSARCOMA STUDIES-1 AND STUDIES-2 [J].
CRIST, WM ;
GARNSEY, L ;
BELTANGADY, MS ;
GEHAN, E ;
RUYMANN, F ;
WEBBER, B ;
HAYS, DM ;
WHARAM, M ;
MAURER, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :443-452
[8]
DEKRAKER J, 1989, CANC CHEMOTHER PHA S, V24, P28
[9]
GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203
[10]
Harmer MH., 1982, TNM CLASSIFICATION P, P23